Israel Charo, MD, PhD is a is a member of Bay City Capital’s Scientific Advisory Board, and also previously served as a Scientist-in-Residence with Bay City Capital from 2009 to 2014. He currently serves as the Senior Vice President of Research at ChemoCentryx, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders, and cancer. Dr. Charo is also a Senior Investigator/Associate Director at the Gladstone Institute of Cardiovascular Disease. He studies the role of chemokines in leukocyte trafficking and inflammation. His group cloned the chemokine receptor CCR2, and showed that it is a major driver for the recruitment of monocyte/macrophages to developing atherosclerotic lesions. Dr. Charo was one of the founding scientists of COR Therapeutics, which was subsequently acquired by Millennium. He has served on the editorial boards of the Journal of Clinical Investigation and the Journal of Biological Chemistry, on the NIH Pathology A Study Section, and on numerous Scientific Advisory Boards.